Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC

BACKGROUND: Despite the recent progress in the treatment and outcome of Non Small Cell Lung Cancer (NSCLC), immunotherapy has still significant limitations reporting a significant proportion of patients not benefiting from therapy, even in patients with high PD-L1 expression. We have previously demo...

Descripción completa

Detalles Bibliográficos
Autores principales: Della Corte, Carminia Maria, Ciaramella, Vincenza, Ramkumar, Kavya, Vicidomini, Giovanni, Fiorelli, Alfonso, Nardone, Valerio, Cappabianca, Salvatore, Cozzolino, Immacolata, Zito Marino, Federica, Di Guida, Gaetano, Wang, Qi, Cardnell, Robert, Gay, Carl Michael, Ciardiello, Davide, Martinelli, Erika, Troiani, Teresa, Martini, Giulia, Napolitano, Stefania, Wang, Jing, Byers, Lauren Averett, Ciardiello, Fortunato, Morgillo, Floriana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682755/
https://www.ncbi.nlm.nih.gov/pubmed/36419183
http://dx.doi.org/10.1186/s12967-022-03730-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682755/
https://www.ncbi.nlm.nih.gov/pubmed/36419183
http://dx.doi.org/10.1186/s12967-022-03730-y

Ejemplares similares